Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**BAY K 8644** is a synthetic small molecule, structurally related to dihydropyridine calcium channel blockers, and functions as an **L-type voltage-gated calcium channel agonist** (specifically, an activator), though it can also exert antagonist/blocking properties in a use- and voltage-dependent manner. It is widely used as a biochemical and pharmacological tool to study the physiology and pharmacology of calcium currents, especially in cardiac and neuronal cells. BAY K 8644 has positive inotropic and vasoconstrictive effects in animal models and can modulate hormone secretion by enhancing calcium-dependent exocytosis. Its behavioral and in vivo cardiovascular effects are dose- and enantiomer-dependent[2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bay k 8644.